EG009

Identification

Name
EG009
Accession Number
DB04907
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

Cerepro is a novel gene-based product for the treatment of patients with operable high grade glioma, a type of malignant brain tumour, given in addition to standard surgery and radiotherapy/chemotherapy. It is being developed by Ark Therapeutics.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • Sitimagene ceradenovec
International/Other Brands
Cerepro
Categories
UNII
Not Available
CAS number
Not Available

Pharmacology

Indication

Intended for the treatment of brain cancer.

Structured Indications
Not Available
Pharmacodynamics

EG009 is comprised of a gene encased in a virus vector. Vectors transfer their gene payload into target cells, a process known as transfection, which use this new genetic material as a blueprint for the production of new beneficial proteins. EG009 uses a well-established adenoviral vector (Ad5) to introduce the gene that causes cells to express a protein called thymidine kinase (TK). Following the standard surgery to remove the solid tumour mass, EG009 is injected through the wall of the cavity left behind by the surgical removal of the solid tumour, into the surrounding healthy brain tissue. In the following days, the healthy cells in the wall of the cavity express TK. Five days after surgery, the drug ganciclovir (GCV) is given to the patient as part of the overall EG009 treatment regimen. Neither TK nor GCV is individually active but they react together to produce a substance which destroys cells when they try to divide. Since cell division is a key characteristic of cancer and the normal brain cells are not dividing, cells that try to divide to form a new tumour around the site of the removal of the original tumour are targeted for destruction by the EG009 treatment. EG009 thus works by harnessing healthy cells to produce the substances necessary to destroy newly growing cancer cells.

Mechanism of action

EG009 works by delivering a gene into the healthy brain cells remaining after the tumour has been removed. These then produce an enzyme that kills the cells trying to divide, preventing a recurrence of a tumour.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of EG009.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of EG009.Experimental
BevacizumabBevacizumab may increase the cardiotoxic activities of EG009.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with EG009.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of EG009.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of EG009.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of EG009.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of EG009.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of EG009.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with EG009.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of EG009.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of EG009.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of EG009.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of EG009.Experimental
OuabainOuabain may decrease the cardiotoxic activities of EG009.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with EG009.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of EG009.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of EG009.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of EG009.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347909845

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 21, 2007 16:23 / Updated on November 06, 2017 06:45